DSIP and melatonin both live under the sleep-research heading, and the comparison between them is lopsided in an instructive way. One is among the most-studied hormones in human physiology, with a defined receptor system and decades of controlled trials. The other is a peptide whose founding observation from 1977 has never been fully explained, and whose mechanism remains genuinely unknown. Setting them side by side is mostly a lesson in how different two compounds under one label can be.
Different molecules from different chemistry
Melatonin is not a peptide at all. It is an indoleamine, a small molecule synthesised from tryptophan in the pineal gland, released nightly under the control of the circadian clock in the suprachiasmatic nucleus. It acts on two dedicated G protein-coupled receptors, MT1 and MT2, found in the clock itself and across many tissues. Its chemistry, receptors and physiology are textbook material, summarised for clinicians in Brzezinski's New England Journal of Medicine review.
DSIP, delta sleep-inducing peptide, is a nine-residue peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). It was isolated by Schoenenberger and Monnier in Basel in 1977 from the cerebral blood of rabbits subjected to electrical stimulation of the thalamus that induced sleep. Infused into recipient rabbits, the purified peptide promoted delta-wave sleep, which named it.
The contrast begins at the level of basic pharmacology. Melatonin has cloned receptors, receptor knockouts, and approved receptor-agonist drugs modelled on it. DSIP, almost fifty years after isolation, has no identified receptor. Kovalzon and Strekalova's review says it in the title: a still unresolved riddle.
What the evidence looks like on each side
Melatonin's human record spans phase-controlled trials in circadian rhythm disorders, jet lag, and sleep onset, with meta-analyses such as Ferracioli-Oda and colleagues quantifying modest but consistent effects on sleep latency and duration. Whatever one concludes about magnitude, the questions have been asked properly: randomised, placebo-controlled, replicated across independent groups.
The DSIP record is thinner in every dimension. After the founding work, animal and small human studies through the 1980s reported effects on sleep structure, but replication was inconsistent, with some studies finding delta-sleep promotion and others none. Small trials explored other territory entirely, including opioid withdrawal and pain modulation, hinting that the peptide's activity, whatever it is, may not be primarily hypnotic. The honest summary of half a century of DSIP work is that the phenomenon that named the peptide has never been pinned to a mechanism, and the field moved on without resolving it.
There is a further chemical oddity: DSIP as a free peptide should be degraded rapidly in plasma, yet the reported effects outlast its expected survival, and the endogenous peptide appears to circulate in bound forms. Even its stability is unresolved.
Why the comparison still gets made
The two compounds meet in practice because both are discussed as tools for sleep-architecture research, melatonin as the established circadian signal and DSIP as a candidate delta-sleep modulator. For a researcher, they occupy opposite ends of the risk-knowledge spectrum. A melatonin protocol stands on defined receptors and a deep evidence base; the interesting questions are refinements. A DSIP protocol is closer to primary exploration; the interesting question is still the original one, and any laboratory working with DSIP vials or the DSIP nasal spray is working on a genuinely open problem rather than confirming settled biology.
That openness is not a defect for research purposes; unexplained phenomena are what research is for. But it should be labelled as what it is, and secondary write-ups that present DSIP as an established sleep peptide are borrowing certainty from melatonin's literature, not reporting DSIP's own.
The takeaway
Melatonin is a small-molecule hormone with receptors, replicated trials and quantified effects. DSIP is a nonapeptide with a striking founding observation, no known receptor, and a literature that never converged. They are compared because both touch sleep, but they are not comparable in evidentiary weight, and the difference is the single most useful thing to know before reading claims about either.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences, 74(3), 1282-1286.
2. Kovalzon, V. M., & Strekalova, T. V. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97(2), 303-309.
3. Brzezinski, A. (1997). Melatonin in humans. New England Journal of Medicine, 336(3), 186-195.
4. Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One, 8(5), e63773.
